A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD.
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2012
At a glance
- Drugs PUR 118 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Biomarker
- 04 Sep 2012 Results were presented at the 22nd Annual Congress of the European Respiratory Society (ERS-2012).
- 04 Sep 2012 Status changed from recruiting to completed.
- 21 Nov 2011 Planned Eed date changed from 1 Aug 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.